Continuum of Core 1 Biomarkers in Preclinical Alzheimer's Disease.

ABSTRACT:

Background and objectives

Biological Staging for Alzheimer's disease (AD) in clinically unimpaired (CU) individuals is critical for early detection efforts. In this study, we evaluated whether Core 1 biomarkers (plasma ptau-217 and amyloid-PET) within Biological Stage A, the earliest biological stage of AD, predicts progression of downstream biomarkers and cognition.

Methods

We used baseline plasma ptau-217 and amyloid-PET, and longitudinal tau-PET, atrophy, and cognition data from the recently completed Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study. PET data were used to identify participants within AD Biological Stage A (amyloid-PET positive and medial temporal tau-PET negative). Within these Stage A participants, linear mixed effects models were used to ex

SUBMITTER: Digma LA 

PROVIDER: S-EPMC12458534 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature